| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3980542 | Cancer Treatment Reviews | 2008 | 10 Pages |
Abstract
Zoledronic acid is the only bisphosphonate that has demonstrated statistically significant, long-term clinical benefits through the prevention and delay of skeletal-related events in patients with metastatic prostate cancer or renal cell carcinoma.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Fred Saad,